
RLAY
Relay Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.775
Open
3.690
VWAP
3.69
Vol
1.66M
Mkt Cap
622.35M
Low
3.580
Amount
6.10M
EV/EBITDA(TTM)
--
Total Shares
132.74M
EV
-89.72M
EV/OCF(TTM)
--
P/S(TTM)
71.87
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.409
-9.11%
--
--
-0.453
-28.1%
--
--
-0.471
-31.74%
Estimates Revision
The market is revising Upward the revenue expectations for Relay Therapeutics, Inc. (RLAY) for FY2025, with the revenue forecasts being adjusted by 173.64% over the past three months. During the same period, the stock price has changed by 10.33%.
Revenue Estimates for FY2025
Revise Upward

+173.64%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-10.34%
In Past 3 Month
Stock Price
Go Up

+10.33%
In Past 3 Month
10 Analyst Rating

241.05% Upside
Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 12.38 USD with a low forecast of 4.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy

241.05% Upside
Current: 3.630

Low
4.00
Averages
12.38
High
17.00

241.05% Upside
Current: 3.630

Low
4.00
Averages
12.38
High
17.00
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$16
2025-03-07
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$16
2025-03-07
Reiterates
Strong Buy
Reason
Stifel
Bradley Canino
Strong Buy
Maintains
$27 → $23
2025-02-27
Reason
Stifel
Bradley Canino
Price Target
$27 → $23
2025-02-27
Maintains
Strong Buy
Reason
Goldman Sachs
Salveen Richter
Strong Buy
Maintains
$20 → $18
2025-02-27
Reason
Goldman Sachs
Salveen Richter
Price Target
$20 → $18
2025-02-27
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$16
2025-01-14
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$16
2025-01-14
Reiterates
Strong Buy
Reason
JMP Securities
Silvan Tuerkcan
Buy
Reiterates
$21
2024-12-12
Reason
JMP Securities
Silvan Tuerkcan
Price Target
$21
2024-12-12
Reiterates
Buy
Reason
Leerink Partners
Christopher Liu
Buy
Maintains
$19 → $18
2024-12-04
Reason
Leerink Partners
Christopher Liu
Price Target
$19 → $18
2024-12-04
Maintains
Buy
Reason
Leerink analyst Christopher Liu lowered the firm's price target on Relay Therapeutics to $18 from $19 and keeps an Outperform rating on the shares after the company announced that lirafugratinib will be out licensed to Elevar Therapeutics. Recall, the company had previously announced its decision to seek a global commercial partner for lirafugratinib during a company event in September 2024. Overall, Leerink thinks this decision is a prudent use of resources given the relatively small size of FGFR2+ populations.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Relay Therapeutics Inc (RLAY.O) is -2.11, compared to its 5-year average forward P/E of -8.58. For a more detailed relative valuation and DCF analysis to assess Relay Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-8.58
Current PE
-2.11
Overvalued PE
0.34
Undervalued PE
-17.50
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-5.80
Current EV/EBITDA
0.14
Overvalued EV/EBITDA
1.94
Undervalued EV/EBITDA
-13.54
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
930.87
Current PS
107.79
Overvalued PS
2199.60
Undervalued PS
-337.87
Financials
Annual
Quarterly
FY2025Q1
YoY :
-23.26%
7.68M
Total Revenue
FY2025Q1
YoY :
-7.95%
-84.87M
Operating Profit
FY2025Q1
YoY :
-5.31%
-77.07M
Net Income after Tax
FY2025Q1
YoY :
-25.81%
-0.46
EPS - Diluted
FY2025Q1
YoY :
+41.25%
-73.59M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+336.23%
-3.55K
FCF Margin - %
FY2025Q1
YoY :
+23.40%
-1.00K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
542.9K
USD
9
3-6
Months
435.4K
USD
14
6-9
Months
4.5M
USD
24
0-12
Months
148.0K
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 352.49% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.2M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
1
10.0M
Volume
Months
3-6
2
2.2M
Volume
Months
6-9
2
1.5M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
542.9K
USD
9
3-6
Months
435.4K
USD
14
6-9
Months
4.5M
USD
24
0-12
Months
148.0K
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
RLAY News & Events
Events Timeline
2025-07-28 (ET)
2025-07-28
09:50:35
Relay Therapeutics has positive read from Celcuity data, says Barclays

2025-06-02 (ET)
2025-06-02
07:32:44
Relay Therapeutics announces updated data for RLY-2608 with Fulvestrant

2025-05-06 (ET)
2025-05-06
14:14:54
Oncology stocks 'bearing the brunt' of Prasad news, says Oppenheimer

Sign Up For More Events
Sign Up For More Events
News
5.0
06-20NewsfilterWith Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
5.0
06-11NewsfilterRelay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
9.0
06-02NewsfilterRelay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Sign Up For More News
People Also Watch

MAX
Mediaalpha Inc
10.040
USD
0.00%

ETNB
89Bio Inc
9.530
USD
+3.36%

EGBN
Eagle Bancorp Inc
16.360
USD
-0.61%

WRLD
World Acceptance Corp
157.800
USD
-0.84%

VLRS
Controladora Vuela Compania de Aviacion SAB de CV
5.790
USD
+4.89%

HUYA
HUYA Inc
3.330
USD
-9.02%

PRTA
Prothena Corporation PLC
6.880
USD
-0.72%

ODP
ODP Corp
18.720
USD
+1.46%

HOV
Hovnanian Enterprises Inc
119.780
USD
-1.54%

CAC
Camden National Corp
37.110
USD
-0.32%
FAQ

What is Relay Therapeutics Inc (RLAY) stock price today?
The current price of RLAY is 3.63 USD — it has increased 0.28 % in the last trading day.

What is Relay Therapeutics Inc (RLAY)'s business?

What is the price predicton of RLAY Stock?

What is Relay Therapeutics Inc (RLAY)'s revenue for the last quarter?

What is Relay Therapeutics Inc (RLAY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Relay Therapeutics Inc (RLAY)'s fundamentals?

How many employees does Relay Therapeutics Inc (RLAY). have?
